Others were suggested that BIM deletion polymorphism was not significantly correlated with the kinase inhibitor efficacy for EGFR-mutated NSCLC, CML and hepatocellular cancer (HCC) patients20, 21, 22, 23. This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.